BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Wednesday, September 23, 2026
📌TL;DR
The FDA advisory panel on Grail's Galleri meets today, 9:00 am to 6:00 pm ET, voting on safety, effectiveness, and benefit risk; the agency's executive summary reports 35.0% sensitivity in PATHFINDER 2, 31.6% in NHS-Galleri, and specificity above 99.7% in both.
Celldex's barzolvolimab met the primary and all key secondary endpoints in both Phase 3 EMBARQ chronic spontaneous urticaria studies (1,939 patients), with a BLA planned for 2027; CLDX fell 11.6%.
Viking's VK2735 maintenance study preserved up to 97% of prior weight loss on every other week dosing and up to 90% on monthly dosing, versus 61% after switching to placebo; VKTX rose 35.7%.
Novartis licensed a preclinical radioligand from China's BoomRay for up to $900 million, per Fierce Biotech, one day after Telix agreed to buy ITM; TLX closed back above the deal's $11.841 strike.
Otsuka and Ionis's ulefnersen met its Phase 3 FUSION primary endpoint in FUS-ALS, the first for the disease, and Amgen's dazodalibep hit its first Sjögren's Phase 3, per the companies and Fierce.
Roche's enicepatide cut HbA1c 2.65% with 15.5% weight loss at week 48 in Phase 2 diabetes, per Fierce Biotech.
⚡ Executive Takeaway
Today's Galleri vote will produce a number, and the number is not where the money is. The three voting questions posted to the docket are standard device panel boilerplate: safe, effective, benefits over risks. The live economics sit in the discussion questions, where the FDA asks whether detecting about one in four early stage cancers supports "claims related to early detection." That phrase will govern how Galleri is labeled, marketed, and reimbursed, and it will bind every MCED filer behind it. Notice what the agency did not ask the panel: nothing on analytical validity, nothing on safety signals. It resolved those itself and left the panel exactly one economic question. So read today in two layers. The tally moves GRAL, which has already prepaid a friendly outcome. The transcript, especially how panelists handle the fact that this test is twice as sensitive where no screening exists, is what Exact, Guardant, and every payer will be quoting a year from now.
Watch the language, not the count. Tomorrow morning we bring you both. 👉 Read Full Analysis
🔬 Diagnostics
The FDA's briefing documents are now public, we read them, and they hand the panel one economic question. GRAL
The full document set posted to the meeting page by Tuesday evening, resolving Monday's oddity where our own fetch found only conflict of interest waivers, so this time the figures come from the FDA executive summary directly. Galleri showed 35.0% sensitivity in PATHFINDER 2 and 31.6% in NHS-Galleri, specificity above 99.7% in both, and positive predictive value of 77.0% and 66.2%. Stage I and II detection ran 24.9% and 20.5%, and the agency asks the panel outright whether that supports early detection claims, while cautioning that episode sensitivity may overstate what is knowable by stage. GRAL closed at 108.52 on panel eve, up 0.5%, holding essentially all of Monday's 33.7% repricing. The panel votes today; the count runs in tomorrow's edition, not this one.
🧪 Immunology
Barzolvolimab met every endpoint that mattered in both Phase 3 hives studies, and Celldex fell 11.6% anyway. CLDX
Both EMBARQ studies in 1,939 chronic spontaneous urticaria patients met the primary and all key secondary endpoints, per the company's release: UAS7 scores dropped roughly 20 points at week 12 versus 10.7 and 11.4 on placebo, complete response at week 24 reached 49.0% to 54.0% on the 150 mg dose versus 15.4% to 17.6% on placebo, and Xolair refractory patients cleared at 41.7% to 55.3% versus 9.3% to 15.1%. The BLA waits until 2027. CLDX closed at 33.51, down 11.6% from Monday's 37.89, our arithmetic; the company disclosed nothing to explain the move and we assign no cause. The readout resolves the tracked catalyst behind Monday's Cue readacross, and the Pro brief maps what a sold win means for the KIT class.
💉 Obesity and Metabolic
Viking put a number on the question every obesity model dodges: how much efficacy survives less frequent dosing. VKTX | NVO
Per Viking's release, VK2735 patients kept up to 97% of prior weight loss on every other week dosing and up to 90% on monthly dosing, versus 61% after switching to placebo, across a 12 week maintenance phase, and the 17.5 mg weekly cohort reached 22% placebo adjusted weight loss at week 33. VKTX closed at 40.85, up 35.7% from Monday's 30.11, our arithmetic. The same morning, Roche's enicepatide met both Phase 2 diabetes endpoints with a 2.65% HbA1c reduction and 15.5% weight loss at week 48, per Fierce Biotech. Novo ADRs slipped another 1.0% to 39.40 in the second session after its capital markets day, with EASD opening Monday in Milan as the next dated test of its promises.
☢️ Radiopharma
Novartis took one day to answer Telix. NVS | TLX
Novartis licensed a preclinical radioligand from Suzhou based BoomRay Therapeutics for up to $900 million in milestones and royalties, per Fierce Biotech, with the upfront undisclosed and the asset unnamed; BoomRay's pipeline spans FAP and Nectin-4 theranostics plus a brain tumor diagnostic. The timing does the talking: the license landed one day after Telix agreed to buy ITM, the supplier of Novartis's lutetium-177. Telix's Nasdaq listed shares rose 5.7% to 11.95, closing back above the $11.841 deal strike they broke on day one; the strike gap referendum we set up yesterday opened in the deal's favor.
🧬 Rare Disease and Neuro
The rarest form of ALS got its first Phase 3 win, and Amgen's quiet Sjögren's bet paid. IONS | AMGN
Ulefnersen, the Ionis discovered antisense drug Otsuka licensed for $10 million upfront in 2024, significantly beat placebo on a week 72 endpoint combining function and survival in the 73 patient primary analysis of the FUSION study in FUS-ALS, per the companies, and Otsuka opened an early access program the same day. FUS mutations drive roughly 0.6% of ALS, often fast moving and often young. Separately, Amgen's dazodalibep improved ESSDAI scores in the 651 patient Oasiz 301 study, its first Phase 3 win in Sjögren's disease, per Fierce Biotech; a second study in milder patients still has to read out. IONS added 1.9%; AMGN rose 4.3% the same session, cause not assigned.
📉 The Tape
Six positive datasets in one session, and the unexplained column still grew. SRRK | RARE | VERA | BHVN
Away from the readouts, the moves without news kept coming. SRRK 51.19, up 6.3%, and RARE 15.615, up 6.6%, both with no news found tonight and both still missing their pricing documents, Isembyld 12 days after approval and Fayuvi six. VERA rose 5.9% to 36.26 with no company disclosure, the same session Vertex talked up a broad kidney disease label. BHVN 14.85, up 4.4%, a second straight unexplained gain with Thursday's 15.6% spike still causeless. DFTX held above its round trip line at 40.32, XENE was flat at 39.09 in a third session of stabilization, ETRA slipped 2.2% to 13.62, 9.2% below issue, and SMMT added 1.3% ahead of its November 14 decision. All closes are exchange closes; all percentages our arithmetic.
📋 Quick Hits
Vertex's inaxaplin cut proteinuria 42.7% at week 13 in Phase 2b patients with APOL1 mediated kidney disease and modest proteinuria, per Fierce Biotech; the pivotal AMPLITUDE interim reads early 2027 and could support accelerated approval.
Boehringer Ingelheim signed an up to $1 billion AI oncology collaboration with Envisagenics, whose SpliceCore platform mines more than 14 million splicing events, per Fierce Biotech; AI drug discovery company Iambic is planning an IPO.
BMS is cutting another 265 New Jersey jobs under its $2 billion savings program, and Travere CEO Eric Dube will step down, per Fierce Pharma; TVTX fell 4.1%.
Lexeo will buy Mantle Therapeutics for $8 million, adding frataxin targeted Friedreich ataxia assets, per Fierce Biotech.
Europe cleared three: NewAmsterdam's obicetrapib (Ubeslo, plus the Evlarco combination), J&J's oral IL-23 receptor peptide icotrokinra, and AbbVie's Rinvoq in juvenile arthritis, per trade press reports.
STAT reports the $245 a month Medicare bridge pilot may hold more benefits for Lilly and Novo than first understood (paywalled, attributed), and compounder Empower drew an FDA warning letter over GLP-1s, per Endpoints.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The complete FDA executive summary tables: both pivotal trials, stage detection, and the screening status split
Every EMBARQ number Celldex released, dose by dose, with the tape that followed
The full Tuesday market board, twenty verified closes
The deadline gauntlet scoreboard heading into tariffs and the GENEROUS deadline
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The split outcome nobody is pricing: how the panel can say yes to the test and no to the label, and the FDA sentence that makes it scientifically respectable
💊 What a clean double Phase 3 win selling 11.6% says about where the chronic hives bar now sits, and who inherits the runway to 2027
📊 The maintenance math: why Viking's 97% number aims directly at the assumption underneath Novo's DKK 150 billion promise
🎯 Plus the week's coming catalysts, with the full calendar returning Friday
Panel day. The webcast runs 9:00 am to 6:00 pm ET, and tomorrow morning we carry the count, the transcript's best lines, and the grade on our own asymmetry call. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →